Acidic solvent improves cisplatin action in in-vitro.

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Cisplatin is a vital chemotherapeutic agent extensively studied in vitro and in vivo.
• Current methods for preparing cisplatin solutions for in vitro assays, such as using dimethyl sulfoxide (DMSO) or normal saline (NS), present significant drawbacks including reduced drug activity, instability, and solubility issues.
• These limitations complicate research efforts aimed at understanding cisplatin's mechanism of action, mitigating its toxicity, and developing novel drug combinations.

Purpose of the Study:

• To introduce and validate a novel solvent system for cisplatin preparation in vitro.
• To address the limitations associated with current cisplatin solubilization methods, specifically instability and reduced efficacy.
• To provide a more reliable and stable method for in vitro cancer research involving cisplatin.

Main Methods:

• A novel solvent mixture, dimethyl sulfoxide-hydrochloric acid (DMSO-HCl), was prepared and utilized for cisplatin dissolution.
• The stability and drug activity of cisplatin dissolved in DMSO-HCl were evaluated and compared to cisplatin dissolved in normal saline (NS).
• The compatibility of cisplatin in DMSO-HCl with other DMSO-solubilized compounds was assessed.

Main Results:

• Cisplatin dissolved in DMSO-HCl demonstrated comparable drug activity to cisplatin dissolved in NS.
• Cisplatin in DMSO-HCl exhibited enhanced stability over extended storage periods compared to NS.
• The DMSO-HCl solvent system mitigated issues related to cisplatin instability, limited solubility, and complications with combined drug formulations.

Conclusions:

• The DMSO-HCl mixture represents a superior alternative solvent for preparing cisplatin solutions for in vitro cancer research.
• This new method enhances cisplatin stability and maintains drug efficacy, overcoming critical limitations of existing protocols.
• The findings offer valuable insights for optimizing cisplatin-based in vitro studies and facilitating the development of combination cancer therapies.